Disease · MONDO_0005051

invasive lobular breast carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. invasive lobular breast carcinoma. Diseases, record MONDO_0005051. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005051

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: invasive lobular breast carcinoma; Open Targets
Open Targets ID: MONDO_0005051; Open Targets
Other names: classic invasive lobular carcinoma, infiltrating lobular adenocarcinoma, infiltrating lobular breast carcinoma, infiltrating lobular carcinoma of breast, infiltrating lobular carcinoma of the breast, invasive lobular adenocarcinoma, invasive lobular carcinoma, invasive lobular carcinoma of breast, invasive lobular carcinoma of the breast, invasive lobular carcinoma, classic type, lobular breast carcinoma, lobular carcinoma; Open Targets
Disease Ontology: DOID:3457; Disease Ontology
NCI Thesaurus: C7950; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 9 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FULVESTRANT	CHEMBL1358	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TAMOXIFEN	CHEMBL83	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ANASTROZOLE	CHEMBL1399	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENTRECTINIB	CHEMBL1983268	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
GOSERELIN	CHEMBL1201247	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IVONESCIMAB	CHEMBL6068451	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PALBOCICLIB	CHEMBL189963	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
REPOTRECTINIB	CHEMBL4298138	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CYP19A1	Aromatase	2	Cytochrome P450 19A1 inhibitor	Phase 2	https://conductscience.org/library/genes/1588	Drugs and targets
ESR1	Estrogen receptor	2	Estrogen receptor alpha antagonist; Estrogen receptor alpha modulator; Estrogen receptor degrader	Phase 2	https://conductscience.org/library/genes/2099	Drugs and targets
NTRK1	High affinity nerve growth factor receptor	2	Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4914	Drugs and targets
NTRK2	BDNF/NT-3 growth factors receptor	2	Neurotrophic tyrosine kinase receptor inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor	Phase 2	https://conductscience.org/library/genes/4915	Drugs and targets
NTRK3	NT-3 growth factor receptor	2	NT-3 growth factor receptor inhibitor; Neurotrophic tyrosine kinase receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4916	Drugs and targets
ROS1	CD74-ROS1	2	CD74-ROS1 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; ROS1-SDC4 inhibitor	Phase 2	https://conductscience.org/library/genes/6098	Drugs and targets
ALK	ALK tyrosine kinase receptor	1	ALK tyrosine kinase receptor inhibitor	Phase 2	https://conductscience.org/library/genes/238	Drugs and targets
CCND1	CDK6/cyclin D1	1	CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/595	Drugs and targets
CD74	CD74-ROS1	1	CD74-ROS1 inhibitor	Phase 2	https://conductscience.org/library/genes/972	Drugs and targets
CDK4	Cyclin-dependent kinase 4/cyclin D1	1	Cyclin-dependent kinase 4/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/1019	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02764541	Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)	Phase 2	195	2023-08-31	Breast Cancer	LETROZOLE, PALBOCICLIB, TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT02206984	Endocrine Response in Women With Invasive Lobular Breast Cancer	Phase 2	201		Breast Cancer	ANASTROZOLE, FULVESTRANT, TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT04551495	Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)	Phase 2	65		Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer	ENTRECTINIB, GOSERELIN, LETROZOLE	Its record names the disease	ClinicalTrials.gov
NCT07229417	A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma	Phase 2	29		Metastatic Endocrine Refractory, Triple Negative Invasive Lobular Carcinoma	IVONESCIMAB	Its record names the disease	ClinicalTrials.gov
NCT06408168	Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)	Phase 2	6		Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma	FULVESTRANT, REPOTRECTINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Arm C Endocrine With Palbociclib vs Arm D Endocrine Therapy Alone: Number of Participants With RCB Response in Arm C and Arm D During the Treatment Phase	10 of 128	3 of 60	188	NCT02764541

Source Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41672025	DERIVED	1	PubMed
41276768	DERIVED	1	PubMed
41272386	DERIVED	1	PubMed
37450351	DERIVED	1	PubMed
35695563	DERIVED	1	PubMed
35119530	DERIVED	1	PubMed
33947745	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005051

GET https://conductscience.org/api/diseases/v1/MONDO_0005051/drugs

API reference For AI assistants